Radius Health Inc. buy tamam
Start price
30.01.18
/
50%
€35.46
Target price
04.11.21
€21.41
Performance (%)
-47.87%
End price
05.11.21
€18.49
Summary
This prediction ended on 05.11.21 with a price of €18.49. The BUY prediction by tamam for Radius Health Inc. performed very badly with a performance of -47.87%. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Radius Health Inc. | - | - | - | - |
iShares Core DAX® | -0.543% | 1.491% | 13.638% | 16.760% |
iShares Nasdaq 100 | -2.696% | -1.235% | 31.879% | 45.155% |
iShares Nikkei 225® | -2.863% | 2.491% | 12.078% | 7.840% |
iShares S&P 500 | -1.105% | 0.013% | 26.888% | 43.056% |
Comments by tamam for this prediction
In the thread Radius Health Inc. diskutieren
Radius Health could Advance 50% With Osteoporosis Treatment
Morgan Stanley analyst initiated coverage of the company with an Overweight rating and a $57 price target.
Radius is set to launch Tymlos, a bone builder for women with osteoporosis, but despite Eli Lilly's presence in the market with Forteo, which fetched the company $1 billion in sales and is exposed to generic competition in 2019, the analyst said Tymlos' pricing is 40 percent lower than Forteo's — and
convenience could help it grab share.
Radius Health is a Conviction Buy!
Kursziel geändert auf 41,414
Kursziel geändert auf 21,414
In the thread Trading Radius Health Inc.
Die von tamam gewählte maximale Laufzeit wurde überschritten